Skingen International, Inc. – Trademark Portfolio
Entity Type: 03
Skingen International, Inc. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 4 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include HEMATIX, CLEOPATRA, XXTRALASH, and SKINGENUITY. The owner is based in Toronto, ON.
19 Alexandra Blvd
Toronto, ON M4R1L8 , CA
Showing of trademarks Trademarks
Trademark Classifications
Skingen International, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Skingen International, Inc. have?
Skingen International, Inc. has 8 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 abandoned, 2 cancelled.
What trademark classes does Skingen International, Inc. file in?
Skingen International, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are Skingen International, Inc.'s most well-known trademarks?
Skingen International, Inc.'s registered trademark portfolio includes well-known marks such as HEMATIX, CLEOPATRA, XXTRALASH, and SKINGENUITY. These are among 5 currently registered trademarks in the portfolio.
What is Skingen International, Inc.'s trademark registration success rate?
Skingen International, Inc. has a 63% trademark registration rate, with 5 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.